Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
denintuzumab mafodotin + rituximab + cyclophosphamide + doxorubicin + prednisone
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of **denintuzumab mafodotin** (an antibody-drug conjugate targeting CD19), **rituximab** (an anti-CD20 monoclonal antibody), **cyclophosphamide** (an alkylating agent), **doxorubicin** (an anthracycline antibiotic cytotoxic agent), and **prednisone** (a corticosteroid). Denintuzumab mafodotin binds to CD19 on B cells, delivering a cytotoxic payload (monomethyl auristatin F) upon internalization; rituximab targets CD20 to induce B cell lysis; cyclophosphamide crosslinks DNA; doxorubicin intercalates DNA and inhibits topoisomerase II; prednisone induces apoptosis and exerts anti-inflammatory effects. The combination was studied as a front-line or salvage therapy for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma grade 3b.
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on denintuzumab mafodotin + rituximab + cyclophosphamide + doxorubicin + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on denintuzumab mafodotin + rituximab + cyclophosphamide + doxorubicin + prednisone.